Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based theranostics company Amorfix Life Sciences has reported that its EP-vCJD blood screening assay can detect sporadic Creutzfeldt-Jakob disease prions using brain material spiked into human plasma at the same sensitivity.
Subscribe to our email newsletter
Amorfix said that this finding supports the company’s platform technology for detecting aggregated misfolded proteins and expands the potential use of the assay to sporadic Creutzfeldt-Jakob disease (sCJD).
The company is seeking to acquire blood and spinal fluid from sCJD patients to assess whether the assay can be used for antemortem diagnosis of this disease.
Neil Cashman, chief scientific officer of Amorfix, said: “sCJD is the most common form of this brain wasting disease and has a profound impact on healthcare because of its potential for patient to patient transmission. An antemortem diagnostic test for sCJD would be an important step forward in managing the risk from this disease in healthcare settings.”